Top

Published in:

01-10-2011 | Case Report

Successful treatment of cyclosporine-A-resistant cytophagic histiocytic panniculitis with tacrolimus

Authors: Yoshishige Miyabe, Yutaka Murata, Yukari Baba, Eisaku Ito, Kenji Nagasaka

Published in: Modern Rheumatology | Issue 5/2011

Abstract

A 34-year-old woman with discoid lupus erythematosus and lupus profundus was admitted to our hospital showing signs of a fever, malaise, and abdominal swelling. Diagnosis of cytophagic histiocytic panniculitis (CHP) was made based on lobular panniculitis with a hemophagocytosis. Treatment with high doses of prednisolone combined with cyclosporine A (CsA) was not effective enough. However, after changing CsA to tacrolimus (TAC), CHP improved. Our case demonstrates that TAC may be a novel therapy for CHP.

Winkelmann RK, Bowie JW. Hemorrhagic diathesis associated with benign histiocytic cytophagic panniculitis and systemic histiocytosis. Arch Intern Med. 1980;140:1460–3.PubMedCrossRef

Yamaguchi M, Ohta A, Ota T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMed

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.PubMedCrossRef

Ostrov BE, Althreya BH, Goldsmith DP, et al. Successful treatment of severe cytophagic histiocytic panniculitis with cyclosporine A. Semin Arthritis Rheum. 1996;25:404–13.PubMedCrossRef

Craig AJ, Cualing H, Smith R, et al. Cytophagic histiocytic panniculitis—a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature. J Am Acad Dermatol. 1998;39:721–36.PubMedCrossRef

Guitart J, Sethi R, Gordon K. Fatal cytophagic histiocytic panniculitis after a short response to cyclosporine. J Eur Acad Dermatol Venereol. 1998;10:267–8.PubMedCrossRef

Behrens EM, Kreiger PA, Cron RQ, et al. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. 2006;33:2081–4.PubMed

Matsue K, Itoh M, Kokubo T, et al. Successful treatment of cytophagic histiocytic panniculitis with modified CHOP-E Cyclophosphamide, adriamycin, vincristine, predonisone, and etoposide. Am J Clin Oncol. 1994;17:470–4.PubMedCrossRef

Koizumi K, Sawada K, Koike T, et al. Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Bone Marrow Transplant. 1997;20:171–3.PubMedCrossRef

10.

Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem. 2000;7:731–48.PubMed

11.

Alegre VA, Winkelmann RK. Histiocytic cytophagic panniculitis. J Am Acad Dermatol. 1989;20:177–85.PubMedCrossRef

12.

Hytiroglou P, Phelps RG, Strauchen JA, et al. Histiocytic cytophagic panniculitis: molecular evidence for a clonal T-cell disorder. J Am Acad Dermatol. 1992;27:333–6.PubMedCrossRef

13.

Fernández RR, Rubio JL, Cano DS, et al. Long-term evolution of cytophagic histiocytic panniculitis. J Cutan Med Surg. 2010;14:136–40.

Title: Successful treatment of cyclosporine-A-resistant cytophagic histiocytic panniculitis with tacrolimus
Authors: Yoshishige Miyabe
Yutaka Murata
Yukari Baba
Eisaku Ito
Kenji Nagasaka
Publication date: 01-10-2011
Publisher: Springer Japan
Published in: Modern Rheumatology / Issue 5/2011
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-011-0435-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene

Erratum to: A case of juvenile idiopathic arthritis exhibiting repair of systemic bone erosion in response to continuation of MTX therapy after achievement of clinical remission

Lobular panniculitis with small vessel vasculitis associated with ulcerative colitis

Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic disease in general

Efficacy of total joint arthroplasty in patients with established rheumatoid arthritis: improved longitudinal effects on disease activity but not on health-related quality of life

Successful treatment of a patient with IgG4-related disease with a paravertebral mass lesion

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials